Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Seoung Jun Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis
Dong Soo Lee, Jin Hyoung Kang, Chang Geol Lee, Seoung Jun Kim, Young Jin Choi, Kyo Young Lee, Yeon Sil Kim
Cancer Res Treat. 2013;45(2):95-102.   Published online June 30, 2013
DOI: https://doi.org/10.4143/crt.2013.45.2.95
AbstractAbstract PDFPubReaderePub
PURPOSE
A number of factors related to overall survival (OS) have been addressed in advanced non-small cell lung cancer (NSCLC). This study was conducted to determine the impact of whole-body metastatic regions on survival outcome in advanced non-squamous NSCLC.
MATERIALS AND METHODS
Between March 2005 and February 2011, 112 eligible patients with newly confirmed stage IV non-squamous NSCLC, available for epidermal growth factor receptor (EGFR) mutation status 18-21 analysis, and accessible for the determination of pretreatment whole-body metastatic regions were enrolled in this retrospective study. The total number of synchronous metastatic regions was scored according to the following disease sites: abdomen/pelvis, lung to lung/pulmonary lymphangitic spread, bone, pleura/pleural effusion/pericardial effusion, neck/axillary lymph nodes, other soft tissue, brain.
RESULTS
The median age of the cohort was 65 years (range, 31 to 88 years). The median whole-body metastatic score was 2 (range, 1 to 6), and bone and lung to lung were the most common metastatic sites. EGFR mutations were observed in 40 (35.7%) patients with a deletion in exon 19 and Leu858Arg mutation in exon 21 being detected in 16 (40.0%) and 19 (47.5%) patients, respectively. Multivariate analysis for OS revealed that treatment factors (p=0.005), performance status (p=0.006), whole-body metastatic score (p<0.001), and EGFR mutation status (p=0.095) were significantly or marginally associated with OS.
CONCLUSION
The results of the present study demonstrated that whole-body metastatic extent strongly affects survival outcome, even after adjustment for other significant variables in advanced non-squamous NSCLC. The clinical validity of more curative multimodal approaches in cohorts with limited metastases remains to be explored.

Citations

Citations to this article as recorded by  
  • Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
    Boyeon Kim, Young Soo Park, Jae Sook Sung, Jong Won Lee, Saet Byeol Lee, Yeul Hong Kim
    Cancer Medicine.2021; 10(1): 372.     CrossRef
  • Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents
    Cláudia Freitas, Maria Jacob, Nuno Tavares, Natália Cruz-Martins, Conceição Souto-Moura, David Araújo, Hélder Novais-Bastos, Vanessa Santos, Gabriela Fernandes, Adriana Magalhães, Venceslau Hespanhol, Henrique Queiroga
    Anti-Cancer Drugs.2021; 32(5): 567.     CrossRef
  • O impacto da histologia do carcinoma pulmonar na frequência das metástases ósseas
    Marcelo Bragança dos Reis Oliveira, Larissa Costa Souza, Ermides Javier Garcia Sampayo, Gustavo Sobral de Carvalho, Fernanda Carvalho de Queiroz Mello, Marcos Eduardo Machado Paschoal
    Revista Brasileira de Ortopedia.2019; 54(05): 524.     CrossRef
  • Brain Metastases at Presentation in Patients With Non–Small Cell Lung Cancer
    Saiama N. Waqar, Sadaf H. Waqar, Kathryn Trinkaus, Carlos A. Gadea, Cliff G. Robinson, Jeffrey Bradley, Mark A. Watson, Varun Puri, Ramaswamy Govindan, Daniel Morgensztern
    American Journal of Clinical Oncology.2018; 41(1): 36.     CrossRef
  • Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer
    Lizet Sanchez, Leacky Muchene, Patricia Lorenzo-Luaces, Carmen Viada, Pedro C. Rodriguez, Sailyn Alfonso, Tania Crombet, Elia Neninger, Ziv Shkedy, Agustin Lage
    Seminars in Oncology.2018; 45(1-2): 52.     CrossRef
  • Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer
    Amanda Jane Williams Gibson, Haocheng Li, Adrijana D’Silva, Roxana A. Tudor, Anifat A. Elegbede, Shannon Mary Otsuka, D. Gwyn Bebb, Winson Y. Cheung
    Medical Oncology.2018;[Epub]     CrossRef
  • PATHOLOGICAL FRACTURES DUE TO BONE METASTASES FROM LUNG CANCER: RISK FACTORS AND SURVIVAL
    Marcelo Bragança dos Reis Oliveira, Bruno de Carvalho Marques, Rosa Aurílio Matos, César Rubens da Costa Fontenelle, Fernanda Carvalho de Queiroz Mello, Marcos Eduardo Machado Paschoal
    Acta Ortopédica Brasileira.2018; 26(6): 388.     CrossRef
  • Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes
    Dong Soo Lee, Kyung Ran Park, Seung Joon Kim, Mi Joo Chung, Yun Hee Lee, Ji Hyun Chang, Jin Hyoung Kang, Sook Hee Hong, Myung Sin Kim, Yeon Sil Kim
    Tumor Biology.2016; 37(1): 619.     CrossRef
  • Distinctive Patterns of Initially Presenting Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung Cancer
    Dong Soo Lee, Yeon S. Kim, Chul S. Kay, Sung H. Kim, Chang D. Yeo, Jin W. Kim, Seung Joon Kim, Young K. Kim, Yoon H. Ko, Jin H. Kang, Kyo Y. Lee
    Medicine.2016; 95(6): e2795.     CrossRef
  • Rare occurrence of cavitation of lung metastases following effective targeted therapy: A case report
    JIACHENG SONG, JING YU, ZHANLONG MA, SHANSHAN LU
    Oncology Letters.2016; 11(2): 1589.     CrossRef
  • Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology
    Hatice Odabas, Arife Ulas, Kubra Aydin, Mevlude Inanc, Asude Aksoy, Dogan Yazilitas, Mehmet Turkeli, Sinemis Yuksel, Ali Inal, Ahmet S. Ekinci, Alper Sevinc, Nebi S. Demirci, Mukremin Uysal, Necati Alkis, Faysal Dane, Mehmet Aliustaoglu, Mahmut Gumus
    Tumor Biology.2015; 36(12): 9641.     CrossRef
  • Clinical Correlation Between Tumor Maximal Standardized Uptake Value in Metabolic Imaging and Metastatic Tumor Characteristics in Advanced Non-small Cell Lung Cancer
    Dong Soo Lee, Seung Joon Kim, Hong Seok Jang, Ie Ryung Yoo, Kyung Ran Park, Sae Jung Na, Kyo Young Lee, Sook Hee Hong, Jin Hyoung Kang, Young Kyoon Kim, Yeon Sil Kim
    Medicine.2015; 94(32): e1304.     CrossRef
  • A case of lung cancer complicated by axillary Castleman's disease
    Manabu Kakizoe, Kousuke Suzuki, Noriyuki Saeki
    The Journal of the Japanese Association for Chest Surgery.2015; 29(6): 722.     CrossRef
  • Non-small cell lung cancer metastasis to the oral cavity: a case report
    JB Olsen, F Sim, A Chandu
    Australian Dental Journal.2014; 59(4): 520.     CrossRef
  • Lung Cancer Coexisting With Ipsilateral Pleural Effusion
    Francisco Rodriguez-Panadero, Beatriz Romero-Romero
    Lung Cancer Management.2014; 3(4): 335.     CrossRef
  • EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
    Ukhyun Jo, Kyong Hwa Park, Young Mi Whang, Jae Sook Sung, Nam Hee Won, Jong Kuk Park, Yeul Hong Kim
    Oncotarget.2014; 5(5): 1265.     CrossRef
  • 11,490 View
  • 76 Download
  • 16 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP